RC-0315 / Remedy Cell - LARVOL DELTA

RC-0315 for treatment of idiopathic pulmonary fibrosis: a partially blinded, randomized, placebo-controlled, single and repeat dose safety & tolerability phase 1b study (ERS 2026) - "All patients are monitored for 12 months with follow up visits after 1 week, 1 month, 6 months, and 12 months. Characteristics of study participants and available safety and efficacy data will be reported."

Clinical • P1 data • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases

Toxicologic Evaluation of RC-0315, a Mesenchymal Stem Cell-Derived Secretome, Following Repeated Intratracheal Administration in Mice. (PubMed, Toxicol Pathol) - "Histopathological examination revealed no RC-0315-related adverse findings in the lungs or other organs, and no local toxicity was evident at the site of administration. These findings support the favorable safety profile of RC-0315 when administered via the clinically intended route."

Journal • Preclinical • Idiopathic Pulmonary Fibrosis • Immunology • Ophthalmology • Pulmonary Disease • Respiratory Diseases

Remedy Cell Announces Initiation of Phase 1b Clinical Trial of RC-0315 in IPF Patients (PRNewswire) - "The primary objective of the RC-0315 First-in-Human, Phase 1b clinical study is to measure drug safety and tolerability. The study's exploratory objectives will assess the effect of RC-0315 on disease pathology, measured through imaging and biomarker analysis in bronchoalveolar lavage (BAL) and plasma samples."

Trial status • Idiopathic Pulmonary Fibrosis

Remedy Cell and Qureight collaborate to integrate deep learning platform into Phase 1b study of RC-0315 in IPF (PRNewswire) - "Remedy Cell...and Qureight Ltd...have partnered to validate RC-0315's mechanism of action in idiopathic pulmonary fibrosis (IPF). The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety and tolerability. The study's exploratory objectives will assess the effect of RC-0315 on disease pathology, measured through imaging and biomarker analysis in bronchoalveolar lavage (BAL) and plasma samples."

Commercial • Idiopathic Pulmonary Fibrosis